[go: up one dir, main page]

AR028026A1 - Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina - Google Patents

Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina

Info

Publication number
AR028026A1
AR028026A1 ARP010101875A ARP010101875A AR028026A1 AR 028026 A1 AR028026 A1 AR 028026A1 AR P010101875 A ARP010101875 A AR P010101875A AR P010101875 A ARP010101875 A AR P010101875A AR 028026 A1 AR028026 A1 AR 028026A1
Authority
AR
Argentina
Prior art keywords
acetilcoline
treatment
receptor agonists
dry eye
eye disease
Prior art date
Application number
ARP010101875A
Other languages
English (en)
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of AR028026A1 publication Critical patent/AR028026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP010101875A 2000-04-21 2001-04-23 Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina AR028026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
AR028026A1 true AR028026A1 (es) 2003-04-23

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101875A AR028026A1 (es) 2000-04-21 2001-04-23 Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina

Country Status (8)

Country Link
US (1) US6277855B1 (es)
EP (1) EP1214062B1 (es)
JP (1) JP2003531168A (es)
AR (1) AR028026A1 (es)
AT (1) ATE253912T1 (es)
AU (1) AU2001253765A1 (es)
DE (1) DE60101201D1 (es)
WO (1) WO2001080844A2 (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
EP1274444B1 (en) * 2000-03-16 2013-05-15 THE McLEAN HOSPITAL CORPORATION Cdp-choline and uridine for the treatment of alcohol abuse
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
AU2003258041A1 (en) * 2002-08-02 2004-02-23 Nutraceutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
CA2502600A1 (en) * 2002-10-18 2004-05-06 Molichem Medicines, Inc. Methods of treating dry eye disease with lantibiotics
JP4667041B2 (ja) * 2002-11-08 2011-04-06 ザ マクレーン ホスピタル コーポレーション タバコ依存症および離脱症状の治療用化合物
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
RU2366428C2 (ru) * 2002-12-20 2009-09-10 Дзе Маклин Хоспитал Корпорейшн Соединения для нормализации цикла сна/бодрствования
CN1738610A (zh) 2003-01-22 2006-02-22 日绊株式会社 眼疾治疗用经皮吸收型制剂、其使用及眼疾治疗药向眼局部组织的转移方法
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005060984A1 (en) * 2003-12-12 2005-07-07 Yee Richard W Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
US7479481B2 (en) * 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
ES2342085T3 (es) * 2004-05-21 2010-07-01 Senju Pharmaceutical Co., Ltd. Preparacion oftalmica de absorcion percutanea que contiene un agonista del receptor muscarinico.
JP4932480B2 (ja) 2004-06-03 2012-05-16 千寿製薬株式会社 アミド化合物を含有する角膜知覚回復剤
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
EP1917964A4 (en) * 2005-07-26 2009-11-11 Senju Pharma Co PERCUTANE RESORBIBLE OPHTHALMIC PREPARATION
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
AU2006294581B2 (en) 2005-09-27 2011-11-03 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
RU2464023C2 (ru) * 2008-05-16 2012-10-20 АКСИС, Инс Лекарственное средство для лечения фибромиалгии
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
KR20110091501A (ko) * 2008-10-14 2011-08-11 싸이코제닉스 아이엔씨. 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도
WO2010091649A2 (en) * 2009-02-11 2010-08-19 Heglund, A.S. A composition for buccal absorption of nicotine for the purpose of smoking cessation
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
AU2011328900B2 (en) 2010-11-16 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
AU2012205791B2 (en) * 2011-01-10 2016-11-03 Invion, Ltd. Use of beta-adrenergic inverse agonists for smoking cessation
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
CA3133869A1 (en) 2011-08-26 2013-03-07 Tissuetech, Inc. Methods of sterilizing fetal support tissues
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (ru) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения блефароконъюнктивальной формы синдрома сухого глаза
WO2014138709A1 (en) * 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
AU2014253754C1 (en) 2013-04-19 2015-07-30 Oculeve, Inc. Nasal stimulation devices and methods
CN106470673B (zh) 2014-02-25 2020-01-31 奥库利维公司 用于鼻泪刺激的聚合物制剂
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
WO2016015025A1 (en) 2014-07-25 2016-01-28 Oculeve, Inc. Stimulation patterns for treating dry eye
IL318427A (en) 2014-10-20 2025-03-01 Oyster Point Pharma Inc Varenicline compound for use as a medication for treating dry eye, increasing tear production and treating eye discomfort and a pramipexole preparation containing varenicline
CA2965514A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
AU2015335776B2 (en) 2014-10-22 2020-09-03 Oculeve, Inc. Stimulation devices and methods for treating dry eye
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
TW201628633A (zh) * 2014-11-05 2016-08-16 組織科技股份有限公司 用於促進神經生長及再生之組成物及方法
AU2015374033B2 (en) 2014-12-31 2020-07-02 Microoptx Inc. Glaucoma treatment devices and methods
EP3297733A1 (fr) * 2015-05-21 2018-03-28 Ophtalmis Monaco Association d'acide lipoique et de taurine en tant qu'agent osmoprotecteur
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
JP6892693B2 (ja) 2015-09-30 2021-06-23 マイクロオプティクス インコーポレイテッド ドライアイ治療装置および方法
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
PT3439661T (pt) * 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
AU2017250514B2 (en) 2016-04-12 2019-12-19 Arturo Solis Herrera Compositions and Methods for Treating Nasal and Paranasal Mucosa Diseases with Nicotinic Acetylcholine Receptor Agonists
AU2017260237A1 (en) 2016-05-02 2018-11-22 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
RU2019118600A (ru) 2016-12-02 2021-01-11 Окулив, Инк. Аппарат и способ составления прогноза синдрома сухого глаза и рекомендаций по лечению
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
TW202317111A (zh) * 2021-07-07 2023-05-01 坎培拉大學 治療及抑制方法
DE102023208057A1 (de) 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
DE69332641T2 (de) 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (de) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
WO2001080844A2 (en) 2001-11-01
EP1214062A2 (en) 2002-06-19
AU2001253765A1 (en) 2001-11-07
DE60101201D1 (de) 2003-12-18
US6277855B1 (en) 2001-08-21
WO2001080844A3 (en) 2002-03-28
ATE253912T1 (de) 2003-11-15
EP1214062B1 (en) 2003-11-12
JP2003531168A (ja) 2003-10-21

Similar Documents

Publication Publication Date Title
AR028026A1 (es) Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina
AR028579A1 (es) Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
NO20030213D0 (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
ATE256141T1 (de) N-pyrazol a2a rezeptor agonisten
DK1192169T3 (da) C-pyrazol A2A receptor-agonister
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
NO20014824L (no) Bicykliske heteroaromatiske forbindelser anvendelige som LH- agonister
EE200100075A (et) 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid
WO2005097140A3 (en) Selective antagonists of a2a adenosine receptors
EP1608315A4 (en) TREATMENT OF IMMUNOLOGICAL DISORDERS USING INTERLEUKIN-21 / INTERLEUKIN-21 RECEPTOR
BR0313373B1 (pt) processo para fabricação contìnua de artigos descartáveis de vestir.
DE60214594D1 (de) Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar)
DE60330392D1 (de) Cb 1 rezeptor inversagonisten
SMAP200600024A (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia
NO20020574L (no) Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
PT1206436E (pt) Retinoides para o tratamento de enfisema
PT1321135E (pt) Composicao para o tigimento de oxidacao das fibras ceratinicas
PL1778239T3 (pl) Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena
NO20043366L (no) Kortikotropinfrigjorende faktor-2 reseptoragonister
IL191271A0 (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders
PT1268482E (pt) Piranoindois para o tratamento de glaucoma
NO20052593D0 (no) Kontinuerlig fremgangsmate for fremstilling av fruktopyranose sulfamat derivater.
AR028111A1 (es) Procedimiento para la produccion de isocianatos

Legal Events

Date Code Title Description
FB Suspension of granting procedure